ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2924

Terminally Differentiated CD8 T Cell Subset Has Distinct Signiture in RA

Masaru Takeshita1, Katsuya Suzuki2, Yoshiaki Kassai3, Maiko Takiguchi3, Yusuke Nakayama4, Keiko Koga3, Rimpei Morita5, Takahiro Miyazaki3, Akihiko Yoshimura5 and Tsutomu Takeuchi2, 1Division of Rheumatology and Clinical Immunology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, 2Keio University School of Medcine, Division of Rheumatology, Department of Internal Medicine, Tokyo, Japan, 3Inflammation Drug Discovery Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company Ltd., Kanagawa, Japan, 4Takeda Pharmaceutical Company Limited, Fujisawa-shi, Japan, 5Department of Microbiology and Immunology, Keio University School of Medicine, Tokyo, Japan

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: T cells and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 15, 2016

Title: T Cell Biology and Targets in Autoimmune Disease - Poster Session II

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Previous reports showed that both CD4 and CD8 T cells were related to the RA disease activity, such as Th17, follicular helper 2, and activated CD8 T cells. On the other hand, T cells can be divided according to developmental stages, and it is controversial whether T cell proceeds development in RA, partly because aging greatly influences T cell development. Recently, the least developed memory T cell subset, stem cell memory T (Tscm), was found among cells with naive phenotype, therefore, peripheral blood (PB) T cells can be divided into naive (Tn), Tscm, central memory (Tcm), and effector memory (Tem) in CD4, and these plus CD45RA+ effector memory (Temra) in CD8. Although human Tscm were reported in patients with bone marrow transplantation, it has not been studied in autoimmune diseases. The purpose of this study was to elucidate the T cell abnormality among each developmental stages including newly identified Tscm in RA patients.

Methods: PB samples from 56 untreated RA patients and 38 healthy controls (HC), and 14 synovial fluid (SF) samples with paired PB from same RA patients were collected. The proportion of each developmental stage and activating status was determined by flow cytometry. Tn, Tscm, Tcm, Tem, and Temra subset from PB of 6 RA and HC were sorted, and analyzed gene expression by microarray.

Results: PB T cells were greatly influenced by age and individual differences, however, the proportion of developed cells tended to increases in RA. Especially, the proportion of CD4 Tscm was significantly high in RA (p=0.02), and CD8 Tscm also tended to be high. In transcriptome analysis, most of subsets were clustered by developmental stage rather than disease, suggesting that influence of disease was not so big among same developmental stages (Fig 1). Remarkably, CD8 Tem and Temra were apparently different between RA and HC. Pathway/upstream analysis showed that this difference may be derived from cytokines such as VEGF, PDGF, and IL-6. In comparison of T cells in PB and SF, the proportion of developed and activated cells was high in SF (Fig 2). Interestingly, most of CCR7+CD45RO-cells in SF, which had been classified as naive, were actually Tscm. In addition, the proportion of activated CD4 and CD8 Tscm in SF were correlated with RA disease activity.

Conclusion: Although the PB T cell in RA had smaller differences with that of HC than expected, several cytokine signatures were found in CD8 Tem and Temra of RA. In SF, almost all T cells, including cells which has been considered naive, were memory cells. Activating status of Tscm in both CD4 and CD8, correlated with RA disease activity, indicating that these subsets participated in RA pathophysiology.


Disclosure: M. Takeshita, None; K. Suzuki, None; Y. Kassai, Takeda Pharmaceutical Co, Ltd., 3; M. Takiguchi, Takeda Pharmaceutical Company Limited, 3; Y. Nakayama, Takeda Pharmaceutical Company Limited, 3; K. Koga, Takeda Pharmaceutical Company Limited, 3; R. Morita, None; T. Miyazaki, Takeda Pharmaceutical Co, Ltd., 3; A. Yoshimura, None; T. Takeuchi, None.

To cite this abstract in AMA style:

Takeshita M, Suzuki K, Kassai Y, Takiguchi M, Nakayama Y, Koga K, Morita R, Miyazaki T, Yoshimura A, Takeuchi T. Terminally Differentiated CD8 T Cell Subset Has Distinct Signiture in RA [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/terminally-differentiated-cd8-t-cell-subset-has-distinct-signiture-in-ra/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/terminally-differentiated-cd8-t-cell-subset-has-distinct-signiture-in-ra/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology